The route to personalized medicine in bladder cancer: where do we stand?

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Recent molecular biology and drug design advances have identified novel therapeutic targets in bladder cancer.
• Key targets include EGFR, FGFR, VEGFR, PI3K/AKT/mTOR pathway, PD-1, COX-2, Aurora kinase A, and miRNA.
• Epithelial to mesenchymal transition (EMT) and cancer stem cells (CSCs) represent promising future therapeutic avenues.

Purpose of the Study:

• To describe emerging molecular targets in bladder cancer.
• To provide an update on ongoing Phase I, II, and III clinical trials for bladder cancer.
• To summarize preliminary results of targeted agents used alone, in sequence, or in combination.

Main Methods:

• Review of recent advances in molecular biology and drug design.
• Analysis of ongoing clinical studies (Phase I, II, and III) in bladder cancer.
• Synthesis of preliminary data on targeted agents and novel therapeutic approaches.

Main Results:

• Identification of multiple novel targets including receptor tyrosine kinases, signaling pathways, immune checkpoints, and microRNAs.
• Ongoing clinical trials are evaluating various targeted agents, combinations, and sequences.
• Early results suggest potential for improved patient outcomes with novel therapeutic strategies.

Conclusions:

• Emerging molecular targets and ongoing clinical trials offer new hope for bladder cancer patients.
• Targeted agents, used in novel combinations and sequences, are key to optimizing treatment strategies.
• Further research and clinical evaluation are crucial to fully realize the potential of these advancements.